Skip to content

Testing Sodium Hypochlorite and Hyaluronic Acid as an Adjunct to Non-Invasive Therapy for Stage III Periodontitis Management

Innovative Clean-Seal Technique Incorporating Sodium Hypochlorite and Hyaluronic Acid as an Adjunct to Non-Invasive Therapy for Stage III Periodontitis Management

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07071467
Enrollment
20
Registered
2025-07-17
Start date
2023-09-01
Completion date
2024-01-10
Last updated
2025-07-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontitis, Periodontitis (Stage 3)

Brief summary

The study was designed to evaluate the concept of the clean & seal, using sodium hypochlorite gel and hyaluronic acid as adjunctive to non-surgical therapy for management of Stage III Periodontitis.

Interventions

OTHERScaling and root planing with sodium hypochlorite and hyaluronic acid

Sodium hypochlorite gel was applied first for 30 seconds, then followed by subgingival instrumentation of the site. Then, 1.8% hyaluronic acid (1.6% cross-linked, 0.2% natural hyaluronic acid ) was applied subgingivally into the periodontal pocket to seal the site.

PROCEDUREScaling and root planing

Pockets were treated with sub-gingival scalling and root planning alone.

Sponsors

Karim Ismail
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Patients of both sexes diagnosed with periodontitis Stage III. * CAL ≥ 5mm or bone loss affecting middle third of the root in more than two adjacent teeth. * PPD ≥ 6mm in more than two adjacent teeth. * Periodontal tooth loss ≤ 4 teeth. * Systemically healthy patients.

Exclusion criteria

* Patient with uncontrolled diabetes. * Pregnant or lactating. * Tobacco smoker ≥ 10 cigarettes/day. * Antibiotic treatment within previous 4 weeks. * Acute periodontal or periapical abscess

Design outcomes

Primary

MeasureTime frameDescription
Plaque accumulationup to 12 weeksThis was assessed using O'Leary plaque index. The O'Leary Plaque Index records the presence or absence of dental plaque on four surfaces (mesial, distal, buccal, lingual) of each tooth. The score ranges from 0% (no plaque) to 100% (plaque on all surfaces), with lower percentages indicating better oral hygiene.
Gingival condition assessmentup to 12 weeksThe Gingival Index of Löe and Silness was used to assess the severity of gingival inflammation based on color, consistency, and bleeding on probing across four areas per tooth. Scores range from 0 (normal gingiva) to 3 (severe inflammation with spontaneous bleeding), with higher scores indicating worse gingival health.

Secondary

MeasureTime frameDescription
Probing depthup to 12 weeksProbing Depth is the measurement of the distance from the gingival margin to the bottom of the periodontal pocket using a periodontal probe. Values typically range from 1-3 mm (healthy) to ≥5 mm (indicative of periodontal disease), with deeper pockets reflecting more severe attachment loss.
Clinical attachment lossup to 12 weeksClinical Attachment Loss measures the distance from the cementoenamel junction to the base of the periodontal pocket, indicating the extent of periodontal support lost. Values range from 0 mm (no attachment loss) to ≥5 mm or more (severe loss), with higher measurements reflecting greater periodontal destruction.

Other

MeasureTime frameDescription
Microbiological assessment of P. gingivalis6 weeksThe bacteriological parameter by using Real Time PCR was used to evaluate the Porphyromonas gingivalis load. Sub-gingival plaque samples were taken by removing of the supra-gingival plaque with curette and cotton pellets before inserting , sterile endodontic paper points in periodontal pocket and leaving them in situ for 10 seconds. The paper points were immediately transferred to sterile , dry cryovials . Paper points were stored frozen at -80 ºC immediately after sample collection until being processed with PCR.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026